Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status

Immune checkpoint inhibitors (ICIs) are standard treatments for patients with lung cancer. PD-1/PD-L1 or CTLA4 antibodies are chosen as the first-line therapy, contributing to the long-term survival and tolerability. Unlike molecular targeting agents, such as gefitinib, lung cancer patients with a p...

Descripció completa

Dades bibliogràfiques

Autors principals:	Kyoichi Kaira, Hisao Imai, Atsuto Mouri, Ou Yamaguchi, Hiroshi Kagamu
Format:	Artigo
Idioma:	Inglês
Publicat:	MDPI AG 2021-11-01
Col·lecció:	Medicina
Matèries:	<sup>18</sup>F-FDG PET PD-1 blockade immunotherapy lung cancer long-term survival metabolic response
Accés en línia:	https://www.mdpi.com/1648-9144/57/11/1273
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!